The company had earlier received GMP (Good Manufacturing Practices) approval from UNICEF.

"Our Ceftriaxone 1gm product has met and surpassed stringent quality criteria, demonstrating our dedication to producing top-tier pharmaceutical solutions. This award not only highlights our product's superior quality but also reinforces our role as a trusted partner in global health initiatives,” Venus Remedies said in a statement.

Venus Remedies is a global pharmaceutical company with a strong focus on fixed dosage injectables. It has a wide range of products and is present in many countries around the world. The company is also committed to research and innovation.

The company’s consolidated net profit declined 4.97% to Rs 10.51 crore in Q4 FY24 from Rs 11.06 crore posted in Q4 FY23. Revenue for Q4 FY24 stood at Rs 195.16 crore in Q4 FY24, up 25.39% YoY.